Noxopharm has received supportive feedback from the US Food & Drug Administration regarding its planned Phase II clinical trial for SOF-SKN™, the company’s autoimmune disease drug candidate. Read more here: www.noxopharm.com/pdf/876066ba...

Noxopharm’s SOF-SKN™ clinical asset for autoimmune skin diseases is set for an extension study in patients with cutaneous lupus (CLE) starting in Q1 CY27. Initial efficacy signals expected in Q2 CY27. Read more here: www.noxopharm.com/pdf/ae468f04...

Noxopharm has released a new investor presentation that highlights the broad potential of the company’s technology, as well as its clinical progress and near-term catalysts. Read it here: www.noxopharm.com/pdf/07c7a9bf...

Promising data has been presented at a US influenza conference following research, conducted by global biopharma company CSL, designed to explore how Noxopharm’s novel oligonucleotides could be used to reduce the reactogenicity of sa-mRNA vaccines. www.noxopharm.com/pdf/38affc62...

New data shows that Noxopharm’s technology can help activate immune cells in response to dying cancer cells, supporting its immuno-oncology potential: www.noxopharm.com/pdf/5d3b9fba...

The breakthrough science underlying the Sofra™ platform was published in Nature Immunology earlier this year. Here’s Noxopharm CEO Dr Olivier Laczka talking about what the paper means for our understanding of the immune system: youtu.be/e10z6QzZNno

Nature Immunology paper explained

YouTube video by Noxopharm

youtu.be

New preclinical data demonstrates the potential of Noxopharm’s cancer-fighting technology, helping the immune system recognise and respond to cellular RNA that would normally go unnoticed. This could pave the way for a new type of cancer treatment. Read more here: www.noxopharm.com/pdf/fbbd07ba...

Noxopharm CEO Dr Olivier Laczka was in good company this week as a panellist at the Bio Connections conference in Melbourne, appearing alongside Dr Michael Wilson of CSL, as well as Pete Tobin of Telix and moderator Associate Professor Tam Nguyen of Monash Health.

Noxopharm CEO Dr Olivier Laczka has been interviewed by the ASX Briefs podcast, talking about the potential of the company’s breakthrough technology across autoimmune and inflammatory diseases, as well as cancer. Listen here: open.spotify.com/episode/7tUX...

NOXOPHARM LTD (NOX) - A New Immune System Discovery Could Change Drug Development

ASX BRIEFS · Episode

open.spotify.com

Noxopharm’s latest quarterly is now out, covering recent milestones as the company continues to push ahead with its innovative technology and collaborations. Read it here: www.noxopharm.com/pdf/b016d12e...

Noxopharm’s partnership with @hudsonresearch.bsky.social Research is at the core of the company’s groundbreaking technology. Here’s CEO Dr Olivier Laczka talking about the relationship with Hudson Institute and how it’s going from strength to strength: youtu.be/dukYQiZtQGw

Noxopharm CEO - Hudson Institute of Medical Research partnership

YouTube video by Noxopharm

youtu.be

Noxopharm has formally requested a pre-Investigational New Drug (IND) meeting with the US Food & Drug Administration – an important milestone in the drug development process. Read more here: www.noxopharm.com/pdf/869f44b5...

A @hudsonresearch.bsky.social team has received a $1 million Medical Research Future Fund grant for a project involving Noxopharm’s Sofra™ platform, which addresses birth injuries that lead to debilitating pelvic floor disorders (PFDs) in women. More here: www.noxopharm.com/pdf/14f66e17...

Noxopharm (ASX:NOX) fast-tracks its immuno-oncology program with a novel human-relevant TLR8 animal model, overcoming key research barriers and amplifying immune response 66-fold. Read more here: www.noxopharm.com/pdf/377d3edc... #Biotech #ImmunoOncology

The breakthrough discovery underlying Noxopharm’s technology has been included in a new overview of global research into the role of TLR7 in systemic lupus. This is high-level recognition from Nature Reviews, and an abstract is available here: www.nature.com/articles/s41...

TLR7 in systemic lupus erythematosus: genetics and emerging therapies - Nature Reviews Rheumatology

Targeting Toll-like receptor 7 (TLR7) represents a promising therapeutic strategy for the treatment of systemic lupus erythematosus (SLE). This Review provides mechanistic insights into the roles of T...

nature.com

Noxopharm’s work with Hudson Institute’s Professor Michael Gantier and his team is highlighted in their latest annual report, which also covers many other areas of fascinating and important research – read it all here: hudson.org.au/wp-content/u...

Noxopharm (ASX:NOX) starts manufacturing SOF-SKN™ to support planned clinical trial targeting cutaneous lupus erythematosus, with low supply chain risks and strong stability. bit.ly/4vBN1Xw

Check out the latest from Noxopharm CEO Dr Olivier Laczka as he outlines the significant potential of the company's technology platform: www.proactiveinvestors.com.au/companies/ne...

Noxopharm CEO discusses Sofra cancer platform

Noxopharm Limited CEO Olivier Laczka talked with Proactive about the company's Sofra™ technology platform and how its discovery around Toll-like...

proactiveinvestors.com.au

Professor Michael Gantier @gantierlab.bsky.social from @hudsonresearch.bsky.social, Noxopharm’s strategic partner, will be a keynote speaker at a free international webinar on 17 June. More details including specific timings and a registration link can be found here: sciforum.net/event/Pharma...

New data from Noxopharm (ASX:NOX) shows its Sofra™ platform can amplify TLR8 immune response 200-fold, unlocking potent new cancer immunotherapy potential in a $185B market by 2035. bit.ly/3Pl6Gvy #biotech #ImmunoOncology

Noxopharm (ASX:NOX) Sofra™ platform data is to be presented by CSL at top global influenza conference, highlighting its potential to enhance self-amplifying mRNA vaccine delivery. bit.ly/4dBMk9k #Biotech #Immunotherapy

Noxopharm (ASX:NOX) advances US FDA pre-IND strategy for SOF-SKN™, targeting $3.3B+ autoimmune skin disease market. Engages global CRO Novotech to boost regulatory and commercial potential. #Biotech #DrugDevelopment bit.ly/49dSDyk

New data demonstrates SOF-16, the active ingredient in SOF-SKN, effectively blocks inflammation in blood and joint fluid samples from lupus and rheumatoid arthritis patients. This supports further development of SOF-SKN for autoimmune diseases. Announcement: www.noxopharm.com/pdf/e6d6d6bf...

Noxopharm has announced positive results from InhaTarget Therapeutics, a company with a unique inhalation-based delivery system that is testing Sofra™ technology platform assets. Read the announcement here: www.noxopharm.com/pdf/deb770c3...

Noxopharm’s latest quarterly is now out, with news of an MoU with US company Tezcat Biosciences, signalling a mutual intent to deepen collaboration in the months ahead and building on the success of an ongoing collaboration. Read the quarterly here: www.noxopharm.com/pdf/2e566eae...

Noxopharm has announced promising new data in support of a future human trial for SOF-SKN™, the company’s cutaneous lupus drug candidate, confirming several important characteristics of the drug and representing a positive step in its refinement. Read more here: www.noxopharm.com/pdf/a094654d...

Noxopharm is pleased to announce the appointment of Dr Olivier Laczka as its new Chief Executive Officer with immediate effect. Dr Laczka has been the driving force behind company’s promising Sofra™ platform for the past several years. Read the announcement here: www.noxopharm.com/pdf/52caff1f...

New Checkpoint in TLR7/8 Sensing Rewrites Innate Immune Rules signals.cytokinesociety.org/2026/03/14/g...

New Checkpoint in TLR7/8 Sensing Rewrites Innate Immune Rules - Biweekly newsletter of The Cytokine Society

A study from the Gantier lab (Hudson Institute/Monash University), published in Nature Immunology, reveals that naturally occurring 2′-O-methyl-guanosine RNA fragments act as potent antagonists of TLR7 and TLR8, binding a previously unknown site to keep the receptors in an inactive state.

signals.cytokinesociety.org

Noxopharm has received a $2,806,583.03 rebate under the Australian Government’s Research and Development Tax Incentive scheme for expenditure during FY 2025. Read more here: www.noxopharm.com/pdf/e2e613a6...

Noxopharm (ASX:NOX) has signed a $5 million At-the-Market equity deal with Acuity Capital, securing flexible standby funding through 2031 with full discretion on share issuance and pricing. www.noxopharm.com/pdf/647ad621...